Do MTRR variants that impair recycling of active B12 contribute to elevated homocysteine?

Clinical and genetic evidence

• MTRR Variants and Homocysteine Levels: The MTRR gene encodes methionine synthase reductase, an enzyme crucial for the regeneration of active vitamin B12. Genetic variations within this gene, most notably the common missense polymorphism rs1801394 (A66G, Ile22Met), are clinically linked to elevated plasma homocysteine.
• Biallelic Mutations: Severe, rare biallelic loss-of-function mutations in MTRR result in the inborn error of cobalamin metabolism classified as the cobalamin E (cblE) defect, presenting with profound hyperhomocysteinemia, megaloblastic anemia, and developmental delay.
• Nutritional Interactions: For individuals with the common rs1801394 variant, the risk of elevated homocysteine is strongly modulated by nutritional status. Studies show that the homozygous GG genotype significantly elevates homocysteine primarily when circulating folate or cobalamin (B12) levels are in the lower reference range.

Mechanistic explanations

• Cofactor Oxidation and Inactivation: Methionine synthase (MTR) requires methylcobalamin (active vitamin B12) to transfer a methyl group to homocysteine, producing methionine. During this catalytic cycle, the cobalamin cofactor occasionally undergoes oxidation to an inactive cob(II)alamin state, rendering the MTR enzyme dormant.
• The Reactivation Cycle: Under physiological conditions, MTRR restores MTR activity by executing a reductive methylation process, transferring electrons from NADPH to regenerate active methylcobalamin.
• Impact of Polymorphisms: The rs1801394 polymorphism alters a critical flavodoxin-like domain of the MTRR enzyme. This alteration decreases its electron-transfer efficiency, leading to suboptimal recycling of oxidized B12 and a subsequent decline in active MTR complexes. Consequently, the rate of homocysteine remethylation drops, leading to its accumulation.

Bottom line

• MTRR genetic variants impair the essential recycling of oxidized cobalamin back to its active methylcobalamin state. This reduces the catalytic activity of methionine synthase and directly contributes to elevated homocysteine levels, a risk that is exacerbated by suboptimal folate and vitamin B12 status.